Skip to main content
Erschienen in: International Journal of Clinical Oncology 1/2018

30.08.2017 | Original Article

Significance of multiple preoperative laboratory abnormalities as prognostic indicators in patients with urothelial carcinoma of the upper urinary tract following radical nephroureterectomy

verfasst von: Masatomo Nishikawa, Hideaki Miyake, Toshifumi Kurahashi, Masato Fujisawa

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of this study was to investigate the prognostic significance of multiple preoperative laboratory abnormalities in upper urinary tract urothelial carcinoma (UUTUC) patients.

Methods

This study included a total of 135 consecutive patients with clinically localized UUTUC who underwent radical nephroureterectomy (RNU). The impact of several preoperative blood-based markers in addition to conventional clinical factors on extravesical recurrence-free survival (eRFS) in these patients was retrospectively evaluated.

Results

Despite the lack of a significant correlation between conventional clinical factors and any of the postoperative pathologic parameters, preoperative laboratory abnormalities were shown to have a significant impact on some pathological factors reflecting an aggressive phenotype as follows—C-reactive protein (CRP) level on pathological stage, De Ritis (aspartate transaminase/alanine transaminase) ratio on nodal involvement, and neutrophil−lymphocyte ratio (NLR) on pathological stage. During the observation period of this study (median 36.1 months), extravesical disease recurrence was detected in 44 (32.6%) of the 135 patients with a 5-year eRFS rate of 62.1%. Of several factors examined, the CRP level, De Ritis ratio, and NRL were significantly correlated with eRFS on univariate analysis. Of these significant factors, the De Ritis ratio and NRL were identified as independent predictors of eRFS on multivariate analysis. Moreover, there were significant differences in eRFS according to the positive numbers of these two independent risk factors.

Conclusions

These findings suggest that it is important to consider laboratory abnormalities, particularly the De Ritis ratio and NLR, to predict disease recurrence following RNU in patients with clinically localized UUTUC.
Literatur
1.
Zurück zum Zitat Raman JD, Messer J, Sielatycki JA et al (2011) Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int 107:1059–1064CrossRefPubMed Raman JD, Messer J, Sielatycki JA et al (2011) Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int 107:1059–1064CrossRefPubMed
2.
Zurück zum Zitat Margulis V, Shariat SF, Matin SF et al (2009) Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115:1224–1233CrossRefPubMed Margulis V, Shariat SF, Matin SF et al (2009) Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115:1224–1233CrossRefPubMed
3.
Zurück zum Zitat Rink M, Ehdaie B, Cha EK et al (2012) Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol 62:677–684CrossRefPubMed Rink M, Ehdaie B, Cha EK et al (2012) Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol 62:677–684CrossRefPubMed
4.
Zurück zum Zitat Roscigno M, Brausi M, Heidenreich A et al (2011) Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 60:776–783CrossRefPubMed Roscigno M, Brausi M, Heidenreich A et al (2011) Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 60:776–783CrossRefPubMed
5.
Zurück zum Zitat Matin SF, Margulis V, Kamat A et al (2010) Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116:3127–3134CrossRefPubMed Matin SF, Margulis V, Kamat A et al (2010) Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116:3127–3134CrossRefPubMed
6.
Zurück zum Zitat Lughezzani G, Burger M, Margulis V et al (2012) Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 62:100–114CrossRefPubMed Lughezzani G, Burger M, Margulis V et al (2012) Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 62:100–114CrossRefPubMed
7.
Zurück zum Zitat Scolieri MJ, Paik ML, Brown SL et al (2000) Limitations of computed tomography in the preoperative staging of upper tract urothelial carcinoma. Urology 56:930–934CrossRefPubMed Scolieri MJ, Paik ML, Brown SL et al (2000) Limitations of computed tomography in the preoperative staging of upper tract urothelial carcinoma. Urology 56:930–934CrossRefPubMed
8.
Zurück zum Zitat Yoshida S, Koga F, Masuda H et al (2014) Role of diffusion-weighted magnetic resonance imaging as an imaging biomarker of urothelial carcinoma. Int J Urol 21:1190–1200CrossRefPubMed Yoshida S, Koga F, Masuda H et al (2014) Role of diffusion-weighted magnetic resonance imaging as an imaging biomarker of urothelial carcinoma. Int J Urol 21:1190–1200CrossRefPubMed
9.
Zurück zum Zitat Ku JH, Kim M, Choi WS et al (2014) Preoperative serum albumin as a prognostic factor in patients with upper urinary tract urothelial carcinoma. Int Braz J Urol 40:753–762CrossRefPubMed Ku JH, Kim M, Choi WS et al (2014) Preoperative serum albumin as a prognostic factor in patients with upper urinary tract urothelial carcinoma. Int Braz J Urol 40:753–762CrossRefPubMed
10.
Zurück zum Zitat Rink M, Sharifi N, Fritsche HM et al (2014) Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 191:316–322CrossRefPubMed Rink M, Sharifi N, Fritsche HM et al (2014) Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 191:316–322CrossRefPubMed
11.
Zurück zum Zitat Saito K, Kawakami S, Ohtsuka Y et al (2007) The impact of preoperative serum C-reactive protein on the prognosis of patients with upperurinary tract urothelial carcinoma treated surgically. BJU Int 100:269–273CrossRefPubMed Saito K, Kawakami S, Ohtsuka Y et al (2007) The impact of preoperative serum C-reactive protein on the prognosis of patients with upperurinary tract urothelial carcinoma treated surgically. BJU Int 100:269–273CrossRefPubMed
12.
Zurück zum Zitat Nishikawa M, Miyake H, Fujisawa M (2016) De Ritis (aspartate transaminase/alanine transaminase) ratio as a significant predictor of recurrence-free survival in patients with upper urinary tract urothelial carcinoma following nephroureterectomy. Urol Oncol 34:417.e9–417.e15CrossRef Nishikawa M, Miyake H, Fujisawa M (2016) De Ritis (aspartate transaminase/alanine transaminase) ratio as a significant predictor of recurrence-free survival in patients with upper urinary tract urothelial carcinoma following nephroureterectomy. Urol Oncol 34:417.e9–417.e15CrossRef
13.
Zurück zum Zitat Morizane S, Yumioka T, Yamaguchi N et al (2015) Risk stratification model, including preoperative serum C-reactive protein and estimated glomerular filtration rate levels, in patients with upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy. Int Urol Nephrol 47:1335–1341CrossRefPubMed Morizane S, Yumioka T, Yamaguchi N et al (2015) Risk stratification model, including preoperative serum C-reactive protein and estimated glomerular filtration rate levels, in patients with upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy. Int Urol Nephrol 47:1335–1341CrossRefPubMed
14.
Zurück zum Zitat Zhang XK, Zhang ZL, Lu X et al (2016) Prognostic significance of preoperative serum lactate dehydrogenase in upper urinary tracturothelial carcinoma. Clin Genitourin Cancer 14(341–345):e3 Zhang XK, Zhang ZL, Lu X et al (2016) Prognostic significance of preoperative serum lactate dehydrogenase in upper urinary tracturothelial carcinoma. Clin Genitourin Cancer 14(341–345):e3
15.
Zurück zum Zitat Dalpiaz O, Ehrlich GC, Mannweiler S et al (2014) Validation of pretreatment neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. BJU Int 114:334–339PubMed Dalpiaz O, Ehrlich GC, Mannweiler S et al (2014) Validation of pretreatment neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. BJU Int 114:334–339PubMed
16.
Zurück zum Zitat Fujita K, Tanigawa G, Imamura R et al (2013) Preoperative serum sodium is associated with cancer-specific survival in patients with upper urinary tract urothelial carcinoma treated bynephroureterectomy. Int J Urol 20:594–601CrossRefPubMed Fujita K, Tanigawa G, Imamura R et al (2013) Preoperative serum sodium is associated with cancer-specific survival in patients with upper urinary tract urothelial carcinoma treated bynephroureterectomy. Int J Urol 20:594–601CrossRefPubMed
17.
Zurück zum Zitat Pichler M, Dalpiaz O, Ehrlich GC et al (2014) Validation of the preoperative plasma fibrinogen level as a prognostic factor in a European cohort of patients with localized upper tract urothelial carcinoma. J Urol 191:920–925CrossRefPubMed Pichler M, Dalpiaz O, Ehrlich GC et al (2014) Validation of the preoperative plasma fibrinogen level as a prognostic factor in a European cohort of patients with localized upper tract urothelial carcinoma. J Urol 191:920–925CrossRefPubMed
18.
Zurück zum Zitat Terakawa T, Miyake H, Hara I et al (2008) Retroperitoneoscopic nephroureterectomy for upper urinary tract cancer: a comparative study with conventional open retroperitoneal nephroureterectomy. J Endourol 22:1693–1699CrossRefPubMed Terakawa T, Miyake H, Hara I et al (2008) Retroperitoneoscopic nephroureterectomy for upper urinary tract cancer: a comparative study with conventional open retroperitoneal nephroureterectomy. J Endourol 22:1693–1699CrossRefPubMed
19.
Zurück zum Zitat Rouprêt M, Babjuk M, Compérat E et al (2015) European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 68:868–879CrossRefPubMed Rouprêt M, Babjuk M, Compérat E et al (2015) European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 68:868–879CrossRefPubMed
21.
Zurück zum Zitat Scholl SM, Pallud C, Beuvon F et al (1994) Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 86:120–126CrossRefPubMed Scholl SM, Pallud C, Beuvon F et al (1994) Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 86:120–126CrossRefPubMed
22.
Zurück zum Zitat Sheu BC, Hsu SM, Ho HN et al (1999) Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma. Cancer 86:1537–1543CrossRefPubMed Sheu BC, Hsu SM, Ho HN et al (1999) Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma. Cancer 86:1537–1543CrossRefPubMed
Metadaten
Titel
Significance of multiple preoperative laboratory abnormalities as prognostic indicators in patients with urothelial carcinoma of the upper urinary tract following radical nephroureterectomy
verfasst von
Masatomo Nishikawa
Hideaki Miyake
Toshifumi Kurahashi
Masato Fujisawa
Publikationsdatum
30.08.2017
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 1/2018
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-017-1184-0

Weitere Artikel der Ausgabe 1/2018

International Journal of Clinical Oncology 1/2018 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.